Last reviewed · How we verify
Anemia Working Group Romania — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Tinzaparin administration | Tinzaparin administration | marketed | ||||
| Heparin administration | Heparin administration | marketed | Anticoagulant | Antithrombin III (indirect); Thrombin and Factor Xa (downstream targets) | Cardiovascular | |
| continuation (darbepoetinum) | continuation (darbepoetinum) | marketed | Erythropoiesis-stimulating agent (ESA) | Erythropoietin receptor (EPOR) | Hematology |
Therapeutic area mix
- Cardiovascular · 1
- Hematology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
- Amgen · 1 shared drug class
- Beijing Chao Yang Hospital · 1 shared drug class
- Australian and New Zealand Intensive Care Research Centre · 1 shared drug class
- Barts & The London NHS Trust · 1 shared drug class
- Beijing Anzhen Hospital · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Affymax · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Anemia Working Group Romania:
- Anemia Working Group Romania pipeline updates — RSS
- Anemia Working Group Romania pipeline updates — Atom
- Anemia Working Group Romania pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Anemia Working Group Romania — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/anemia-working-group-romania. Accessed 2026-05-16.